Literature DB >> 24687891

Parkinson's disease: recent advances.

Regina Katzenschlager1.   

Abstract

While a curative treatment for Parkinson's disease remains elusive, our understanding of disease mechanisms as well as preclinical and pre-motor early manifestations has improved greatly over the past years. An agent with proven disease modifying properties has not yet been identified but symptomatic treatment options for affected patients have improved. For patients with motor complications, this includes invasive approaches such as deep brain stimulation and continuous device-aided drug delivery. The many facets of non-motor problems patients are faced with have finally been fully recognized and have become the target of treatment trials, as have been non-pharmacological approaches.

Entities:  

Mesh:

Substances:

Year:  2014        PMID: 24687891     DOI: 10.1007/s00415-014-7308-9

Source DB:  PubMed          Journal:  J Neurol        ISSN: 0340-5354            Impact factor:   4.849


  27 in total

Review 1.  The Movement Disorder Society Evidence-Based Medicine Review Update: Treatments for the motor symptoms of Parkinson's disease.

Authors:  Susan H Fox; Regina Katzenschlager; Shen-Yang Lim; Bernard Ravina; Klaus Seppi; Miguel Coelho; Werner Poewe; Olivier Rascol; Christopher G Goetz; Cristina Sampaio
Journal:  Mov Disord       Date:  2011-10       Impact factor: 10.338

2.  Comparing exercise in Parkinson's disease--the Berlin LSVT®BIG study.

Authors:  Georg Ebersbach; Almut Ebersbach; Daniela Edler; Olaf Kaufhold; Matthias Kusch; Andreas Kupsch; Jörg Wissel
Journal:  Mov Disord       Date:  2010-09-15       Impact factor: 10.338

3.  Antipsychotic medication treatment for mild hallucinations in Parkinson's disease: Positive impact on long-term worsening.

Authors:  Christopher G Goetz; Wenqing Fan; Sue Leurgans
Journal:  Mov Disord       Date:  2008-08-15       Impact factor: 10.338

4.  Risk factors and prodromal markers and the development of Parkinson's disease.

Authors:  Stefanie Lerche; Klaus Seppi; Stefanie Behnke; Inga Liepelt-Scarfone; Jana Godau; Philipp Mahlknecht; Alexandra Gaenslen; Kathrin Brockmann; Karin Srulijes; Heiko Huber; Isabel Wurster; Heike Stockner; Stefan Kiechl; Johann Willeit; Arno Gasperi; Klaus Fassbender; Werner Poewe; Daniela Berg
Journal:  J Neurol       Date:  2013-11-05       Impact factor: 4.849

5.  Levodopa-carbidopa intestinal gel in advanced Parkinson's disease open-label study: interim results.

Authors:  Hubert H Fernandez; Arvydas Vanagunas; Per Odin; Alberto J Espay; Robert A Hauser; David G Standaert; Krai Chatamra; Janet Benesh; Yili Pritchett; Steven L Hass; Robert A Lenz
Journal:  Parkinsonism Relat Disord       Date:  2013-01-01       Impact factor: 4.891

6.  Neurostimulation for Parkinson's disease with early motor complications.

Authors:  W M M Schuepbach; J Rau; K Knudsen; J Volkmann; P Krack; L Timmermann; T D Hälbig; H Hesekamp; S M Navarro; N Meier; D Falk; M Mehdorn; S Paschen; M Maarouf; M T Barbe; G R Fink; A Kupsch; D Gruber; G-H Schneider; E Seigneuret; A Kistner; P Chaynes; F Ory-Magne; C Brefel Courbon; J Vesper; A Schnitzler; L Wojtecki; J-L Houeto; B Bataille; D Maltête; P Damier; S Raoul; F Sixel-Doering; D Hellwig; A Gharabaghi; R Krüger; M O Pinsker; F Amtage; J-M Régis; T Witjas; S Thobois; P Mertens; M Kloss; A Hartmann; W H Oertel; B Post; H Speelman; Y Agid; C Schade-Brittinger; G Deuschl
Journal:  N Engl J Med       Date:  2013-02-14       Impact factor: 91.245

7.  Randomized clinical trial of 3 types of physical exercise for patients with Parkinson disease.

Authors:  Lisa M Shulman; Leslie I Katzel; Frederick M Ivey; John D Sorkin; Knachelle Favors; Karen E Anderson; Barbara A Smith; Stephen G Reich; William J Weiner; Richard F Macko
Journal:  JAMA Neurol       Date:  2013-02       Impact factor: 18.302

8.  Neurodegenerative disease status and post-mortem pathology in idiopathic rapid-eye-movement sleep behaviour disorder: an observational cohort study.

Authors:  Alex Iranzo; Eduard Tolosa; Ellen Gelpi; José Luis Molinuevo; Francesc Valldeoriola; Mónica Serradell; Raquel Sanchez-Valle; Isabel Vilaseca; Francisco Lomeña; Dolores Vilas; Albert Lladó; Carles Gaig; Joan Santamaria
Journal:  Lancet Neurol       Date:  2013-04-03       Impact factor: 44.182

9.  Risk of Parkinson disease after depression: a nationwide population-based study.

Authors:  Cheng-Che Shen; Shih-Jen Tsai; Chin-Lin Perng; Benjamin Ing-Tiau Kuo; Albert C Yang
Journal:  Neurology       Date:  2013-10-02       Impact factor: 9.910

10.  Association of cerebrospinal fluid β-amyloid 1-42, T-tau, P-tau181, and α-synuclein levels with clinical features of drug-naive patients with early Parkinson disease.

Authors:  Ju-Hee Kang; David J Irwin; Alice S Chen-Plotkin; Andrew Siderowf; Chelsea Caspell; Christopher S Coffey; Teresa Waligórska; Peggy Taylor; Sarah Pan; Mark Frasier; Kenneth Marek; Karl Kieburtz; Danna Jennings; Tanya Simuni; Caroline M Tanner; Andrew Singleton; Arthur W Toga; Sohini Chowdhury; Brit Mollenhauer; John Q Trojanowski; Leslie M Shaw
Journal:  JAMA Neurol       Date:  2013-10       Impact factor: 18.302

View more
  3 in total

1.  Clinical features of Parkinson's disease patients are associated with therapeutic misconception and willingness to participate in clinical trials.

Authors:  Emmi Reijula; Anna-Maija Pietilä; Arja Halkoaho; Tuomas Selander; Kirsti Martikainen; Reetta Kälviäinen; Tapani Keränen
Journal:  Trials       Date:  2017-09-29       Impact factor: 2.279

Review 2.  Synthetic biology and therapeutic strategies for the degenerating brain: Synthetic biology approaches can transform classical cell and gene therapies, to provide new cures for neurodegenerative diseases.

Authors:  Carmen Agustín-Pavón; Mark Isalan
Journal:  Bioessays       Date:  2014-08-06       Impact factor: 4.345

3.  Lentivirus-mediated Persephin over-expression in Parkinson's disease rats.

Authors:  Xiao-Feng Yin; Hua-Min Xu; Yun-Xia Jiang; Yun-Lai Zhi; Yu-Xiu Liu; Heng-Wei Xiang; Kai Liu; Xiao-Dong Ding; Peng Sun
Journal:  Neural Regen Res       Date:  2015-11       Impact factor: 5.135

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.